Healthcare / BiotechnologyLSE
$6.07
-0.18 (-2.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.5M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-21.5%
↓Gross Margin
38.0%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-26.7%
FCF CAGR
—
FCF margin
-203.2%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $870000.0 · net income $-1.8M · FCF $-1.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $870000.00 | $870000.00 | $644000.00 | $457000.00 | $2.2M |
| Net Income | $-1.8M | $-1.8M | $-2.0M | $2.6M | $6.3M |
| EBITDA | $-2.1M | $-2.1M | $-1.5M | $2.7M | $6.5M |
| EPS | -0.02 | -0.02 | -0.02 | 0.03 | — |
| Gross Margin | 38.0% | 38.0% | 49.7% | 53.4% | 50.7% |
| Operating Margin | -260.5% | -260.5% | -263.4% | -2301.8% | -61.7% |
| Net Margin | -207.5% | -207.5% | -316.6% | 566.1% | 282.9% |
| Balance Sheet | |||||
| Debt/Equity | — | — | — | — | 0.05 |
| Current Ratio | 4.61 | 4.61 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.8M | $-1.8M | $-1.5M | $-1.3M | $-1.8M |
| Returns | |||||
| ROE | -21.5% | -21.5% | -23.0% | 23.7% | 34.5% |
| Valuation | |||||
| P/E | — | — | — | 530.58 | — |
| EV/EBITDA | — | — | — | 515.51 | 607.42 |
| P/B | 70.72 | 70.72 | 261.77 | 126.08 | 218.19 |
| Growth & Yield | |||||
| Revenue Growth | 35.1% | 35.1% | 40.9% | -79.3% | — |
| EPS Growth | 17.9% | 17.9% | -180.6% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
-55.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.